Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1.
JA, P.C., P, N., CM, F.S., D, D.C., KL, T., KJ, N., & P, B. (2026). Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1.. Endocrinology and metabolism clinics of North America. https://doi.org/10.1016/j.ecl.2026.04.008
JA PC, P N, CM FS, D DC, KL T, KJ N, et al. Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1.. Endocrinology and metabolism clinics of North America. 2026; doi: 10.1016/j.ecl.2026.04.008
JA PC, P N, CM FS, et al. Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1.[J]. Endocrinology and metabolism clinics of North America. 2026. DOI: 10.1016/j.ecl.2026.04.008.
@article{ja2026,
author = {Pinzon Cortes JA and Narongkiatikhun P and Fuhri Snethlage CM and Del Castillo D and Tommerdahl KL and Nadeau KJ and Bjornstad P},
title = {Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1.},
journal = {Endocrinology and metabolism clinics of North America},
year = {2026},
doi = {10.1016/j.ecl.2026.04.008},
note = {PMID: 42526992},
}
TY - JOUR AU - Pinzon Cortes JA AU - Narongkiatikhun P AU - Fuhri Snethlage CM AU - Del Castillo D AU - Tommerdahl KL AU - Nadeau KJ AU - Bjornstad P TI - Beyond Glycemia in T1D: The Hidden Burden of Insulin Resistance and Cardiorenal Risk in Type 1 Diabetes-Part 1. T2 - Endocrinology and metabolism clinics of North America PY - 2026 DO - 10.1016/j.ecl.2026.04.008 AN - PMID:42526992 ER -
Insulin resistance (IR) is an underrecognized feature of type 1 diabetes (T1D), present even in lean individuals. Rising obesity rates have further amplified this burden, creating a mixed metabolic phenotype that accelerates cardiorenal disease. Paradoxically, despite fewer traditional cardiovascular risk factors, individuals with T1D experience higher rates of cardiorenal complications than those with type 2 diabetes, a gap not fully explained by glycemic control. This article examines the epidemiologic, pathophysiologic, and mechanistic underpinnings of this hidden cardiorenal risk, including key drivers of end-organ damage. Broader therapeutic interventions targeting IR in T1D are essential to prevent future cardiorenal disease.